(VIANEWS) – Cronos Group (NASDAQ: CRON) experienced an extraordinary spike in share prices over just 10 sessions from EUR1.98 to EUR2.61. This comes after five consecutive days of gains on the NASDAQ exchange platform; both were up 0.16% at EUR16,428.82 respectively. The jump is likely attributed to positive market sentiment and investor trust in Cronos Group’s prospects; yet its last closing price 1.14% lower than its 52-week high of EUR2.64.
About Cronos Group
Cronos Group Inc. is an industry-leading cannabinoid company focused on cultivating, producing and marketing high-quality cannabis products across Canada, Israel and Germany. Through their three iconic brands – Spinach, Lord Jones and PEACE NATURALS – Cronos offers a diverse range of dried flower, pre-rolls, oils vaporizers edibles cannabis tinctures to customers worldwide. Established in 2012 and headquartered in Toronto Canada – Cronos Group Inc is dedicated to offering innovative premium cannabis experiences.
Yearly Analysis
Here is a concise analysis of Cronos Group stock:
Yearly Top and Bottom ValueCronos Group’s stock is currently trading at EUR2.61, well below its 52-week high of EUR2.64, yet significantly above its 52-week low of EUR1.64; suggesting an upward trend.
Anticipated Sales Growth for Cronos GroupThis year is expected to experience a sales growth rate of 15.1% which bodes well for future company performance. Next year is anticipated to experience slightly reduced growth of 14.1% but still shows positive momentum for Cronos.
Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)Cronos Group currently stands at an EBITDA value of -1.17 which indicates it is operating at a loss, which should cause investors to be concerned.
Overall, Cronos Group’s stock appears to be trading below its 52-week high and significantly above its 52-week low indicating an upward trend in value. Sales growth should increase this year and next, giving investors hope about future performance; however, their negative EBITDA value may cause concern; investors should carefully consider this factor before making investment decisions.
Quarter Analysis
Earnings Per Share (EPS) Cronos Group’s Earnings Per Share is projected to grow 67.8% year over year with current quarter EPS at 0.07.
Market Capitaisation Its Cronos Group currently boasts a market cap of 1.33B and holds 571.96M outstanding shares.
Price to Earnings Ratio (PE Ratio)The Price-Earnings Ratio of Cronos Group stands at 18.4, which is below its industry average of 45.4 and suggests that the stock may be undervalued.
Price to Sales Ratio (PS Ratio) Cronos Group’s PS Ratio stands at 2.9, which is relatively low compared to its industry average of 12. This indicates that its shares may be undervalued. Dividend Yield Cronos Group does not pay out dividends at this time.
Conclusion: Cronos Group is a fast-growing cannabis company with low PE and PS ratios that indicate it may be undervalued. Unfortunately, however, no dividend is offered and this could deter some investors. Regardless, if growth potential in cannabis industries at low valuation is what matters to you then Cronos Group stock may be worth consideration.
Equity Analysis
Earnings per Share (EPS) is a financial metric used to measure how much profit belongs to each outstanding share of a company’s stock. Cronos Group currently generates an EPS loss per share – this could cause concern among investors looking for companies with profitable operations.
Return on Equity (ROE) is another financial metric that measures profitability relative to shareholder investments in equity. Cronos Group currently shows an ROE of -6.3% which indicates it is not currently producing profits for its shareholders and may indicate either ineffective use of equity to generate profits, or financial difficulties within the business.
These financial metrics suggest that Cronos Group may not be profitable right now and investors should carefully consider this data when making an investment decision about Cronos.
More news about Cronos Group (CRON).
